Biosketch / Results /
Dimitris George Placantonakis, M.D., Ph.D.Assistant Professor; Dir Neurosurgical Laboratory for Stem Cell Resch
Department of Neurosurgery (Neurosurgery)
Clinical Addresses530 FIRST AVENUE
NEW YORK, NY 10016
Hours: Thu. 2 - 6
Handicap Access: yes
Medical ExpertiseBrain Tumors, Meningioma, Glioma, Pituitary Adenoma
Dr. Placantonakis obtained his MD and PhD degrees from NYU School of Medicine's MSTP Program. At NYU, he was elected to the Alpha Omega Alpha National Honor Medical Society and received the Alpha Omega Alpha award for the highest scholastic rating in his medical school class. He then moved to Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center for his neurosurgical residency training with Drs. Phil Stieg and Phil Gutin. Within his residency, he completed a 2-year postdoctoral research fellowship with Drs. Lorenz Studer and Viviane Tabar at Memorial Sloan-Kettering, studying human embryonic stem cell biology. He has received numerous awards for his work, including the Congress of Neurological Surgeons Resident Award, the Neurosurgery Research and Education Foundation Research Fellowship, the New York Society for Neurosurgery Resident Award, and the Distinguished Housestaff Award at Weill Cornell Medical College.
Dr. Placantonakis is interested in the management of brain tumors, including gliomas, pituitary adenomas, meningiomas and metastases. He has received extensive training in intraoperative functional mapping and transnasal endoscopic approaches. He is also the Director of the Neurosurgical Laboratory for Stem Cell Research that studies glioblastoma stem cell and human embryonic stem cell biology. In particular, Dr. Placantonakis' laboratory works on identifying distinct types of cancer stem cells in glioblastoma and modeling the origin of glioma using human embryonic stem cells. His laboratory is funded by the National Institutes of Health (NIH), NYULMC's Cancer Institute and NYULMC's Clinical and Translational Science Institute.
InsuranceAETNA HMO, AETNA INDEMNITY, AETNA MEDICARE, AETNA POS, AETNA PPO/EPO, EBCBS EPO, EBCBS HLTHY NY, EBCBS HMO, EBCBS INDEMNITY, EBCBS MEDIBLUE, EBCBS PATHWAYS / PATHWAYS ENHANCED, EBCBS POS, EBCBS PPO, HIP ACCESS I, HIP ACCESS II, HIP CHLD HLTH, HIP EPO/PPO, HIP HMO, HIP MEDICARE, HIP POS, HOTEL TRADES, LOCAL 1199 PPO, MULTIPLAN/PHCS PPO, Medicare, OXFORD EXCHANGE, OXFORD FREEDOM, Oxford Liberty, Oxford Medicare, Tricare, UHC EPO, UHC HMO, UHC MEDICARE, UHC POS, UHC PPO, UHC TOP TIER, UNITED EXCHANGE- COMPASS
Insurance Disclaimer: Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have changed.
Education1995-2003 — NYU School of Medicine, Medical Education
2003-2010 — Cornell University Medical College (Neurosurgery), Residency Training
2003-2010 — Cornell University Medical College (Neurosurgery), Internship
2003-2010 — Memorial Sloan-Kettering Cancer Center (Neurosurgery), Residency Training
2006-2008 — Memorial Sloan-Ketteriing Cancer Center (No Value Specified), Clinical Fellowships
Dr. Placantonakis obtained his MD/PhD degree in Neuroscience from NYU School of Medicine and completed a postdoctoral fellowship in human embryonic stem cell biology with Drs. Lorenz Studer and Viviane Tabar at Memorial Sloan-Kettering. He was also trained in Neurosurgery at Weill Cornell Medical College and Memorial Sloan-Kettering. At NYU, he is a tenure-track physician-scientist dividing his time between his neurosurgical practice and the laboratory. Dr. Placantonakis has an interest in the treatment of gliomas and brain tumors in general. The Neurosurgical Laboratory for Stem Cell Research, which is headed by Dr. Placantonakis, studies stem cell biology in the context of glioma, a malignant brain tumor. We adapt human embryonic stem cell and genetic technologies to model oncogenic processes, with the goal of understanding the early steps in glioma formation and developing translational applications, such as high-throughput drug screening and biomarker identification. Furthermore, we use genetic approaches and patients' tissue to generate models for high-grade gliomas, with emphasis on the role of stem cells in pathogenesis and new therapeutic approaches that directly target them. Our ultimate goal is to translate our laboratory findings to new therapies and diagnostic tests for patients with glioma.
Dr. Placantonakis' laboratory is funded by the National Institutes of Health (NIH), NYULMC's Cancer Institute and NYULMC's Clinical and Translational Science Institute.